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The effects of 5 days β-alanine supplementation on the velocity and the percentage 
o2max at the lactate threshold. 
Abstract       Matthew Johnson 
Purpose: To assess the effect of 5 days β-alanine supplementation on the velocity and the 
percentage of ・O2max   (%・O2max) at the lactate threshold (Tlac) during treadmill running.  
Method: Using a double-blind, placebo-control, repeated measures, cross-over design, 6 
participants (4 male, 2 female) undertook a Tlac test using a motorised treadmill on 3 separate 
occasions. For 5 days prior to each test participants ingested β-alanine (50mg·kg-1·d-1) or an 
equal amount of maltodextrin (placebo). Participants performed a control trial where no 
supplements were ingested prior to testing (control). The velocity, %・O2max, ・O2, blood 
lactate, heart rate (HR) and RPE at the Tlac were measured during each trial. Significant 
differences between the 3 trials were assessed via one-way repeated-measures analysis of 
variance (p ≤ 0.05).  
Results:  There was no significant difference (p = 0.369) in the velocity at the Tlac between 
the β-alanine (10.17 ± 0.98 km·h-1), placebo (10.33 ± 1.03 km·h-1) or the control trials (10.83 
± 1.16km·h-1). There was no significant difference (p = 0.087) in %・O2max at the Tlac between 
the β-alanine (75.21 ± 6.84%), placebo (75.93 ± 7.32%) or control trials (69.94 ± 7.39). This 
was coupled with a non significant difference in ・O2 between the 3 trials (p = 0.103). Blood 
lactate was not significantly different (p = 0.628) between the β-alanine, placebo and control 
trials (4.1 ± 1.2, 3.7 ± 1.5 and 4.0 ± 1.8mmol·L, respectively).  HR and RPE at the Tlac 
were unchanged between trials (p > 0.05). 
Conclusion: The data suggests that 5 days β-alanine supplementation has no effect on the 
velocity or %・O2max at the Tlac during treadmill running. A five day supplementation period 
may not be sufficient to augment muscle carnosine concentrations to elicit an ergogenic 
effect.     
 v
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1. Introduction 
 For many years athletes of all levels have sought to gain an advantage over 
their competitors. Genetic endowment and an effective periodised training programme 
are without doubt imperative to success (Ahmetov, Williams, Popov et al., 2009; 
Ostrander, Huson & Ostrander, 2009). In attempts to attain success at the top level 
athletes have adopted all means necessary to boost their performance. Strategies like 
alternative training methods (Foster, Hector, Welsh et al., 1995), hypnotherapy 
(Caird, McKenzie & Sleivert, 1999), special diets (Burke, Keins & Ivy, 2001), the use 
of new equipment (Nigg, Stefanyshyn, Cole, Stergiou & Miller, 2003) or nutritional 
supplements (Maughan, King & Lea, 2004), are but a few examples. At elite level 
genetic ability and training techniques are likely to be maximised and, therefore, any 
means of gaining an advantage need to be explored. One avenue of exploration open 
to athletes is the use of nutritional supplements. A substance taken with the intent of 
improving performance or enhancing physical working capacity is referred to as being 
ergogenic (McArdle, Katch & Katch, 2007; Maughan, 1999). There are hundreds of 
proposed ergogenic supplements. Few, however, are supported by clinical trials 
demonstrating the ergogenic effect of these substances. The use of supplementation in 
athletes is widespread (Braun, Koehler, Geyer, Kleiner, Mester, et al., 2009). Many 
athletes chose to use supplements based on marketing claims and myths, without 
being aware of whether the substance has been scientifically proven to be ergogenic 
(Maughan, Depiesse & Geyer, 2007). Such actions may actually impede performance 
and more importantly result in serious health consequences. Therefore, it is essential 
that new supplements are clinically trialled by scientists, academics and researchers 
before being recommended to athletes and coaches. In addition to protecting the 
health of athletes, testing new substances could expand current knowledge in 
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physiology and biochemistry and help determine how these substances exert their 
ergogenic effect.  
 Nutritional ergogenic supplements are taken with one goal in mind – to 
improve performance. How they achieve this ultimate goal may differ depending on 
the substance in question. For example, some supplements are taken to enhance 
physiological adaptation following training; while others are taken to enhance energy 
availability or utilisation. The enhancement of energy availability would inevitably 
delay fatigue and augment physical working capacity. Alternatively, fatigue can be 
delayed by supplementing with a substance that reduces the concentrations of 
metabolic by-products from energy delivery. These metabolic by-products alter the 
internal environment which results in attenuations of muscle performance (Allen, 
Lamb & Westerblad, 2008).     
 
2. Literature Review 
2.1 Fatigue 
 Maintaining cellular homeostasis, specifically acid-base balance, becomes 
increasingly problematic during high-intensity exercise due to the amplified rate of 
lactate and/or proton release as the anaerobic glycolytic system begins to predominate 
(Spriet, Howlett & Heigenhauser, 2000). In an order to attempt to maintain acid-base 
balance several chemical buffering systems exist. These are divided into extracellular 
and intracellular buffers. Extracellular buffers include bicarbonate, plasma phosphates 
and plasma proteins. Intracellular buffers include histidine containing dipeptides 
(HCD), organic and inorganic phosphates and haemoglobin in the erythrocyte (Burton 
& Post, 2001). Scientists traditionally understood that lactate production was a 
consequence of a reduced oxygen supply forcing the muscle into anaerobic 
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metabolism (Katz & Sahlin, 1988). However, research over the last three to four 
decades has questioned traditional belief, and suggests that aerobic metabolism 
produces lactate when exercising at intensities of above 50 percent maximum oxygen 
uptake (・O2max) (Gladden, 2004; Spriet et al., 2000). During light exercise (< 50 
percent ・O2max) pyruvate and the reduced equivalent of nicotinamide adenine 
dinucleotide (NAD+), NADH, are transported into the mitochondria for complete 
oxidation, and therefore lactate production is low. As exercise intensity increases so 
does the demand for adenosine triphosphate (ATP), thereby increasing the reliance on 
glycolytic ATP production. The production of NADH and pyruvate are increased and 
the capacity of the transport systems for pyruvate and NADH become exceeded. In a 
bid to maintain the glycolytic rate NAD+ needs to be continually regenerated in order 
to accept the H+ formed from the reduction of phosphoglyceraldehyde. As the 
concentration of NAD+ becomes limited, the reduction of pyruvate to lactic acid is 
augmented as it provides a means of preventing the build up of H+ in the cytosol. 
Consequently, lactate concentrations begin to rise. In solution lactic acid disassociates 
forming the salt sodium lactate and H+ (Robergs, 2000). The rise in H+ causes 
decreases in intramuscular pH which interfere with the excitation-contraction 
coupling process of skeletal muscle, which, in turn, leads to decreases in power output 
and fatigue (Fitts & Holloszy, 1976). The implication of lactate in fatigue is still the 
topic of debate, with recent work suggesting that lactate has no direct impact on 
fatigue (Robergs, Ghiasvand & Parker, 2004). The concomitant increase in lactate and 
H+ does not imply cause and effect. Whether or not lactate is the cause of fatigue per 
se, lactate production during exercise provides an indication of glycolytic ATP 
production and a marker of H+ accumulation. It can therefore be used as a relative 
marker of exercise intensity and fatigue.  
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2.2 Endurance performance 
 Endurance running performance is dependent on a high rate of oxidative 
phosphorylation for the resynthesis of ATP. Success during endurance running 
requires the integration of cardiovascular, neurological and metabolic factors, and the 
cooperation of these systems to transfer ATP into the highest attained velocity (Coyle, 
2007; Hawley & Spargo, 2007; Spriet, 2007). Several physiological variables have 
been identified as strong determinants of endurance running performance. The 
resultant integration of these physiological variables is to attain the highest velocity 
(the performance velocity), whilst maintaining a high rate of oxidative ATP 
production (Coyle, 1995, Coyle, Joyner & Coyle, 2008). Three important 
determinants of endurance running performance include ・O2max, the lactate threshold 
(Tlac) and running economy. During long distance races energy is predominantly 
derived from oxidative ATP production. ・O2max therefore has obvious importance as 
this represents the upper limit for aerobic energy production (Basset & Howley, 
2000). Several investigations have identified a relationship between ・O2max and 
endurance running performance (Foster, 1983; Hagan, Smith & Gettman, 1981).  
Nevertheless, other physiological variables have been suggested to be stronger 
determinants of endurance performance (Costill, Branam, Eddy & Sparks, 1971; 
Davies & Thompson, 1979; Farrell, Wilmore, Coyle, Billing & Costill, 1979; Fay, 
Londeree, LaFontaine & Volek, 1989; Hagan, Upton, Duncan & Gettman, 1987; 
LaFontaine, Londeree & Spath, 1981). Another determinant of endurance running, 
and one that influences the performance velocity, is the velocity at Tlac (Coyle, 1999). 
The volume of oxygen (・O2) consumed at the Tlac has a direct impact on the velocity 
at Tlac. When the ・O2 is expressed as a percentage of ・O2max it often coincides with the 
Tlac (Joyner & Coyle, 2008). The percentage of ・O2max at which the Tlac occurs gives 
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an indication of the pace that can be maintained for a prolonged period (Bassett & 
Howley, 2000) 
 
2.3 Lactate threshold (Tlac) 
 The Tlac can be defined as the exercise intensity (velocity or ・O2) that precedes 
the non-linear accumulation in blood lactate concentrations (Ivy, Withers, Van 
Handel, Elger & Costill, 1980). The Tlac is measured during a graded exercise test 
(GXT) and a blood sample is taken at several different exercise intensities to assess 
lactate concentrations. These are then plotted on a graph against exercise intensity and 
used to determine the Tlac. The point at which lactate levels increase in a non-linear 
fashion from resting value represents the Tlac (Ivy et al., 1980). Over the years 
investigators have used a variety of methods to describe and identity the Tlac. For 
instance, Farrell et al. (1979) used the term “onset of plasma lactate accumulation” 
and identified this as the point on the graph directly preceding the exponential rise in 
plasma lactate. In contrast, Sjödin and Jacobs (1981) used a fixed lactate 
concentration of 4mmol·l-1 to identify this benchmark, while other laboratories (Allen, 
Seals, Hurley, Eshani & Hagberg, 1995) utilised a lactate concentration of 2.5 
mmol·L-1.  While having a fixed blood lactate concentration makes identification of 
the Tlac easier, it limits individuality and further more, variations in lactate tolerance 
may mean a physiological threshold does not occur at exactly 4mmol·l-1 in all 
individuals (Bosquet, Léger & Legros, 2002). Another methodological approach 
utilised to pinpoint the Tlac is known as the Dmax method (Cheng, Kuipers, Snyder et 
al., 1992). After the blood-lactate curve has been plotted, a straight line is fitted from 
the two end points of the blood-lactate curve. The intensity associated with the widest 
point between the blood lactate curve and the straight line denotes the Tlac. The Dmax 
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method of identifying the Tlac has been reported to be highly correlated (r = 0.86, p < 
0.001) with running performance in both males and females (Nicholson & Sleivert, 
2000).  
 Training at the Tlac, or close to it, has been suggested to provide the optimum 
stimulus to enhance the Tlac (Tanaka, Watanabe, Konishi et al., 1986). However, 
further experimental evidence to support this is sparse (Midgley, McNaughton & 
Jones, 2007). In the study by Tanaka et al. (1986) the subjects were middle distance 
runners who typically performed high intensity training as part of their periodised 
training programme. Therefore, the change in training load (duration and intensity) 
may be the reason why the Tlac was enhanced with the inclusion of sub-maximal 
endurance training. In subjects already accustomed to longer sub-maximal runs no 
alteration in the Tlac is observed following further increases in training volume at the 
intensity corresponding to the Tlac (Londeree, 1997; Weltman, Seip, Snead, et al., 
1992). An alternative approach to enhancing the Tlac involves the ingestion of certain 
supplements prior to exercise. Edge, Bishop and Goodman (2006) reported a 
significant improvement in the Tlac of 16 untrained women following eight weeks 
sodium bicarbonate (NaHCO3) ingestion whilst undertaking a high-intensity interval 
training programme. Both the placebo group (training alone) and the NaHCO3 group 
displayed improvements in the Tlac (15% vs 26%, p ≤ 0.05); however, the 
improvements in the NaHCO3 group were significantly greater (p ≤ 0.05). Other 
evidence suggests short term metabolic alkalosis, via NaHCO3 ingestion, can 
influence ・O2 kinetics during a GXT (Zoladz, Szkutnik, Duda, Majerczak & 
Korzeniewski, 2005). Another buffering agent under recent investigation is beta 
alanine (β-alanine).  
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2.4 Carnosine 
 Beta alanine (β-alanine) is the rate-limiting precursor for the biosynthesis of 
the intramuscular buffer carnosine (Bate-Smith, 1938). Carnosine is a dipetide 
synthesised in skeletal muscle and brain tissue (Bakardjiev & Bauer, 1994; Bauer & 
Schulz, 1994) from the essential amino acid histidine and the non-essential β-amino 
acid β-alanine. This is catalysed by the enzyme carnosine synthetase (Kalyankar & 
Meister, 1959). Carnosine was originally discovered by a Russian scientist at the turn 
of the 20th Century (as cited by Boldyrev, 2007) but it was not until several decades 
later that its role in mammals as a muscular buffer was identified (Bate-Smith, 1938). 
More recently, research has elucidated that carnosine could participate in other 
important physiological roles, such as an antioxidant, an enzyme regulator and 
enhancing sarcoplasmic reticulum calcium release (Begum, Cunliffe & Leveritt, 
2005).  Evidence of carnosines primary role as an intramuscular buffer can be found 
from studies with different species (Abe, 2000).  Certain species, who rely heavily on 
anaerobic energy production (racing dogs, horses), typically possess greater 
concentrations of intramuscular carnosine than species which are less active, for 
example humans (Harris, Marlin, Dunnett, Snow & Hultman, 1990). Additionally, 
higher concentrations of carnosine are reported in species which are exposed to 
extended periods of hypoxia (Davey, 1960). Little piked whales, for example, are 
capable of prolonged breath-hold dives and possesses a high concentration of HCD 
due to the hypoxic conditions it frequently inhabits (Abe, 2000).  
 Human carnosine concentrations show large inter-individual variation. Factors 
influencing concentrations include gender, age, training status, diet and β-alanine 
supplementation. Mannion et al. (1992) demonstrated that untrained males have 
significantly greater levels of carnosine in the quadriceps femoris compared to 
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females (21.3 ± 4.2μmol·g-1dw vs 17.5 ± 4.8 μmol·g-1dw, p ˂ 0.05). As with species 
whose environment and activity permits long periods of hypoxia or acidosis, it 
appears that individual fibre types in humans demonstrate variation in carnosine 
content depending on the activity they are predominantly recruited for. Fibres which 
are primarily glycolytic (type II) have greater levels of carnosine than that of fibres 
that are recruited for oxidative energy provision. Harris, Dunnett and Greenhaff 
(1998) took muscle biopsies from the vastus lateralis of four subjects and stained 
them to determine the fibre type and determined carnosine content of each fibre by 
liquid chromatography. The results indicate that type II fibres have significantly 
greater carnosine levels compared to type I fibres (23.2 mmol·kg-1dw vs 10.5 
mmol·kg-1dw, p ≤ 0.05). Similar results were previously reported in the leg muscle of 
horses (Sewell,, Harris, Marlin & Dunnett, 1992). Collectively, these results further 
reinforce the primary role of carnosine as an intramuscular buffer as type II fibres 
predominantly replenish ATP via anaerobic glycolysis. 
 It may, therefore, seem logical that repetitive high-intensity training (i.e. 
training that would tax the anaerobic system) would inevitably augment muscle 
carnosine levels due to the greater recruitment of type II fibres during this type of 
activity (Linnamo, Newton, Hakkinen et al., 2000). Interestingly, a recent 
investigation (Tallon, Harris, Boobis, Fallowfield & Wise, 2005) reported that well 
trained bodybuilders have over double the amount of carnosine than that of their age-
matched counterparts (43.01 ± 8.27 vs. 19.75 ± 3.31 mmol·kg-1dry weight, p ≤ 0.001). 
It was suggested that these levels of carnosine may be responsible for as much as 19% 
of the total muscle buffering capacity. In comparison, it was reported that in untrained 
individuals, the contribution of carnosine to total muscle buffering capacity is 
between seven and eight percent (Mannion, Jakeman, Dunnett, Harris & Willan, 
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1992; Tallon et al., 2005). However, the extent to which this is a purely training 
response cannot be easily identified from the data of Tallon et al (2005), as the two 
groups differed in many aspects besides their training regimes (e.g. fibre type 
proportion, diet, supplement usage, drugs etc). Nevertheless, comparisons between 
sprinters, rowers, marathon runners and untrained subjects support similar inquisitions 
regarding supramaximal training and improved carnosine concentrations (Parkhouse, 
McKenzie, Hochachka & Ovalle, 1985). The sprinters and rowers had significantly 
greater concentrations of carnosine compared to the marathon runners and the 
untrained individuals (4.93 ± 0.76 μmol·g-1dw, 5.04 ± 0.72 μmol·g-1dw vs 2.80 ± 0.74 
μmol·g-1dw, 3.75 ± 0.86 μmol·g-1dw, p ≤ 0.01). In a study assessing the effects of 
sprint training on muscle carnosine levels (Suzuki, Ito, Takahashi & Takamatsu, 
2004), eight weeks of training was enough to exacerbate concentrations by more than 
double the preliminary amount. Collectively, this suggests that long term training may 
potentially enhance muscle carnosine concentration. However, the degree of 
improvement in carnosine concentrations is dependent on the type of training that is 
under taken. 
 Carnosine is not present in plants and, therefore, is absent from fruit and 
vegetables. As a result muscle carnosine concentrations of vegetarians maybe 
reduced. Indeed that was the case in a recent investigation assessing the variation in 
muscle carnosine content of vegetarians and omnivores (Harris, Jones, Hill, et al., 
2007). Vegetarians were reported to have lower levels of carnosine in the vastus 
lateralis compared to those who ate a mixed diet (12.9 ± 2.8 mmol·kg-1dm and 23.3 ± 
5.4 mmol·kg-1dm, respectively). Furthermore in another study, ingestion of chicken 
breast extract, which contains considerable amount of carnosine, was also reported to 
increase carnosine concentrations in male subjects (Sato, Suzuki, Morimatsu & 
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Takamatsu, 2003). Carnosine ingested from meat is hydrolysed, in the gastro-
intestinal tract, into histidine and β-alanine by the enzyme carnosinase. The lack of 
this enzyme in muscle cells implies intramuscular carnosine is a stable compound 
(Otani, Okumura, Hashida-Okumura & Nagai, 2005). The two constituents are 
transported via the circulatory system to the brain and skeletal muscle, as these tissues 
possess the carnosine synthetase enzyme responsible for carnosine synthesis (Bauer & 
Schulz, 1994). The consequent uptake of β-alanine is dependent on its relative 
concentrations in the blood (Dunnett & Harris, 1999). Due to the greater affinity of 
carnosine synthetase for histidine, the rate limiting substrate for carnosine synthesis is 
therefore β-alanine (Artioli, Gualano, Smith, Stout & Lancha, 2010).  
 
2.5 Beta alanine supplementation  
 β-alanine supplementation is, therefore, the most effective way to augment 
skeletal muscle carnosine concentrations (Harris, Tallon, Dunnett, et al., 2006). The 
degree of improvement in carnosine concentrations appears to be dose dependent with 
greater doses increasing carnosine levels to a greater extent. Table 2.1 gives a 
summary of the studies assessing carnosine increases following β-alanine 
supplementation. Harris et al. (2006) assessed dosages of 3.2 g·kg-1d-1 and 6.4 g·kg-1d-
1 for a period of 28 days and reported that muscle carnosine levels had increased by 
42 percent and 64 percent, respectively. 
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Table 2.1. Summary of β-alanine supplementation on muscle carnosine levels 
Reference Subjects Dose Carnosine increase Protocol 
Performance 
enhancement 
Baguet et 
al., 2009 
15 
untrained 
males 
4.8g·d-1 
for 4-
5weeks 
Soleus 39%* 
Tibialis 27%* 
Gastrocnemius 
23%* 
No ↑ in Pl 
group 
 
N.A N.A 
Derave et 
al., 2007 
15 sprint 
trained 
males 
4.8g·d-1 
for 4 
weeks 
Soleus 47% 
Gastrocnemius 
37% 
No ↑ in Pl 
group 
Matched-
paired 
design. 5 x 
30 isokinetic 
knee 
extensions, 
isometric 
contraction 
at 45% max, 
400m run 
time  
 
Bouts 4 & 5 
isokinetic peak 
torque ↑* by 
6.1 & 3.8%, 
respectively in 
β-Al group 
only. 
Harris et 
al., 2006 
21 
physically 
active 
males 
4weeks of: 
1) 3.2g 
g·d-1 of β-
Al 
2) 6.4 g·d-
1 of β-Al 
3) 1000 – 
2000g of 
carnosine 
4) placebo 
 
↑ in v.lateralis: 
1) 42.1%* 
2) 64.2%* 
3) 65.8%* 
4) no change 
  
Hill at al., 
2007 
25 
physically 
active 
males 
4 – 6.4 
g·d-1 for 4 
wks. 8 
subjects 
continued 
to supple-
ment for 
10 weeks 
 
↑ in v.lateralis  
by 58% and 
80% for 4 and 
10 wk, 
respectively. = 
↑ in all fibres 
Cycle 
ergometer 
test at 110% 
work rate 
max to 
assess TWD 
13% and 
16.2%↑* in 
TWD after 4 
and 10 wk, 
respectively. 
No change in 
placebo group. 
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Table 2.1 continued… 
Reference Subjects Dose Carnosine increase Protocol 
Performance 
enhancement 
Kendrick 
et al., 
2009 
7 
recreation
ally active 
males 
6.4g·d-1 
for 4 
weeks 
↑ in v.lateralis 
of β-Al group 
only. Trained 
leg 52.2% 
untrained leg 
28.3% 
 = ↑ in all fibre 
types.  
4 weeks of 
single-
legged 
isokinetic 
training, 
with  or 
without β-Al 
supplementa
tion 
N/A 
 
Note: * significant (p < 0.05), ↑ = increase, Pl – placebo group, β-Al = beta alanine 
group, v.lateralis = vastus lateralis, TWD = total work done.  
 
If the dosing period is extended from four weeks to ten weeks, it has been suggested 
that carnosine concentrations can be further augmented, by an additional 16 percent, 
when dosing with 6.4 g·kg-1d-1 (Hill, Harris, Kim, et al., 2007). Other laboratories 
(Baguet, Reyngoudt, Poitter, et al., 2009; Derave, Özdemir, Harris, et al., 2007; 
Harris, Jones. Kim, et al., 2009; Kendrick, Kim, Harris, et al., 2009) have also 
demonstrated that muscle carnosine levels are increased following β-alanine 
supplementation for several weeks (Table 2.1). Alternatively, shorter dosing periods 
of 14 days have been employed (Harris, Hill, Sale, et al., 2006; Ponte, Harris, Hill et 
al., 2007). While muscle carnosine levels were not assessed in the aforementioned 
studies, performance was still improved using a 14 day supplementation protocol. 
While there seems to be little question of its effectiveness, there appears to be a 
noticeable inter-individual variation in muscular carnosine increases between subjects 
following β-alanine supplementation. Derave et al. (2007) reported increases of 
between 28 and 89 percent in the soleus and increases between 22 and 53 percent in 
the gastrocnemius of trained sprinters. This suggests that carnosine levels can be 
increased in trained athletes as well as untrained individuals when supplementing with 
β-alanine for four weeks. Although the average increase in carnosine levels 
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(gastrocnemius 37 percent) is slightly lower than those reported in other 
investigations (vastus lateralis 50 percent) using untrained subjects (Hill et al., 2007), 
it demonstrates that supplementation can augment carnosine levels in those with 
initially high levels of intramuscular carnosine. Albeit, more work is clearly 
warranted using highly trained subjects. The variation reported in the degree of 
carnosine improvement between the study of Derave et al. (2007) and Hill et al. 
(2007) could reflect the differences in the site where the muscle sample was extracted 
from. In another study, samples taken from the gastrocnemius muscle of 15 untrained 
subjects after four weeks β-alanine supplementation (Baguet et al., 2009), resulted in 
a 23 percent increase in carnosine concentrations. The contrasting findings of Derave 
et al. (2007) and Baguet et al. (2009) with regards to muscle carnosine increases may 
be related to the training regimes of the participants. The subjects of Derave et al. 
(2007) were all involved in sprint training of a relatively high standard as they were 
preparing for the indoor 400m season; the subjects from the Baguet et al. (2009) 
laboratory were reported as not being involved in regular training.  It may, therefore, 
be a genetic factor as the sprinters could have a greater proportion of type II muscle 
fibres (Parkhouse et al., 1985), which have been reported to contain greater amounts 
of carnosine (Harris et al., 1998) and may result in a more rapid synthesis of carnosine 
than type I fibres.  A recent investigation (Kendrick et al., 2009) assessed the 
differences in carnosine increases between type I and type II muscle fibres, following 
β-alanine supplementation. The results indicted that carnosine content was increased 
by 52, 35 and 65 percent in type I, type IIa and type IIb fibres, respectively. 
Interestingly, the greatest increase in carnosine was reported in the fibres where 
anaerobic energy delivery predominates, possibly due to enhanced carnosine 
synthetase activity (Tsubone, Yoshikawa, Okada & Abe, 2007) or/and enhanced β-
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alanine transport (Bakardjiev & Bauer, 1994). This hypothesis has yet to be confirmed 
(Baguet et al., 2009). 
 
 
2.6 β-alanine effects on exercise performance 
 Given the greater concentrations of carnosine in muscle fibres that 
predominantly produce ATP via anaerobic glycolysis, it would be coherent that β-
alanine supplementation could theoretically enhance exercise performance in 
situations where a strong muscular metabolic acidosis is elicited, and thus becomes a 
limiting factor (i.e. 60 seconds to 5 minutes).  Table 2.2 summaries the effect of β-
alanine supplementation on performance indices.  
 
Table 2.2 Summary of the effects of β-alanine supplementation on performance 
Reference Subjects Dose Carnosine increase Protocol 
Performance 
enhancement 
Baguet et 
al., 2010 
14 
physicall
y active 
students 
4.8 g·d-1 
for 4 wks 
Not 
measured 
MP design. 6 
min cycling on 
ergometer @ 
50% between 
VT and ・O2max. 
・O2 kinetics were 
recorded. Blood 
samples taken to 
assess pH, 
lactate, 
bicarbonate and 
base excess.  
 
Exercise-
induced acidosis 
was reduced* by 
19% in β-Al 
group. No effect 
on the O2 
deficit.  
Derave et 
al., 2007 
15 sprint 
trained 
males 
4.8g·d-1 
for 4 wks 
Soleus 
47%* 
Gastroc - 
nemius 
37%* 
 
 
 
 
MP design. 5 x 
30 isokinetic 
knee extensions, 
isometric 
contraction at 
45% max, 400m 
run time  
 
Bout 4 & 5 peak 
torque 
increased* by 
6.1 & 3.8%, 
respectively in 
β-Al group only 
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Table 2.2 continued… 
Reference Subjects Dose Carnosine increase Protocol 
Performance 
enhancement 
Hoffman 
et al., 2007 
26 male 
strength/
power 
athletes 
4.5g·d-1 
for 30 
days. 9 
days 
during 
training 
Not 
measured 
30sec Wingate 
test & 
intermittent 
sprint test. 
Subjective 
feelings of 
fatigue, soreness 
and practice 
intensity. 
Training logs 
recorded. 
 
Subjective 
feeling of 
fatigue lower* 
in β-Al group. 
No difference in 
any other 
measures 
between β-Al 
and Pl groups 
Jordon et 
al., 2010 
17 
recreatio
nally 
active 
males  
6g·d-1 for 
4 wks 
Not 
measured 
GXT on 
treadmill to 
assess if ・O2max, 
%・O2max, ・O2, HR 
or %HRmax at 
OBLA were 
affected.  
 
%・O2max, HR 
and %HRmax 
were improved* 
following 
supplementation 
Smith et 
al., 2009 
46 
untraine
d males 
6g·d-1 for 3 
wks 3g·d-1 
for 
remaining 
3 wks 
Not 
measured 
β-Al supp and  
interval training 
for 6 wks. 
・O2max, TTE, VT 
and TWD 
assessed before, 
during and after. 
Gains in ・O2max, 
TTE and TWD 
significantly* 
greater during 
final 3 wks of 
training. 
 
 
Stout et 
al., 2007 
22 
untraine
d 
females 
3.2 – 6.4 
g·d-1 for 4 
wks  
Not 
measured 
Continuous 
cycle ergometer 
test to assess 
PWCFT, VT, 
TTE and ・O2max 
In β-Al group 
13.9, 12.6 and 
2.5% increase* 
in VT, PWCFT 
and TTE, 
respectively. No 
effect on ・O2max.  
 
 
 
 
 
 
 
 
 
 
 
Table 2.2 continued… 
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Reference Subjects Dose Carnosine increase Protocol 
Performance 
enhancement 
Stout et 
al., 2006 
51 
untraine
d males 
1) placebo 
34g 
2) CR 
5.25g 
3) β-Al 
1.6g 
4) β-Al + 
CR. 
Taken 4x 
a day for 
6days then 
2x a day 
for next 22 
days.  
 
Not 
measured 
Continuous 
cycle ergometer 
test to assess 
PWCFT 
14.5% increase* 
in PWCFT in 
the β-Al group. 
11% increase in 
CR group. No 
additional 
effects of 
combined β-Al 
and CR.   
Stout et 
al., 2008 
9 males, 
17 
females, 
both un-
trained 
 
2.4 g·d-1  
for 90 
days 
Not 
measure 
Discontinuous 
cycle ergometer 
test to assess 
PWCFT.  
 
28.6% increase* 
at PWCFT in the 
β-Al group. No 
change in Pl 
Sweeney 
et al., 2010 
20 
strength/
power 
trained 
males 
4 g·d-1 for 
5 wks 
Not 
measured 
2sets 5 x 5sec 
sprints 45sec rest 
between sprints. 
2 min rest 
between sets. 
 
No performance 
enhancement 
Van 
Theinen et 
al., 2009 
17 
moderate 
– well 
trained 
cyclists 
 
 
 
 
 
 
 
2 – 4 g·d-1 
for 8 wks 
 
 
 
 
 
 
Not 
measured 
110min cycling 
at 50% and 90% 
MLSS. 110min 
TT 
Significantly* 
greater peak 
(11.4%) and 
mean (5.0%) 
power output 
during TT 
 
 
 
 
 
 
 
 
 
Table 2.2 continued… 
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Reference Subjects Dose Carnosine increase Protocol 
Performance 
enhancement 
Zoeller et 
al., 2007 
55 
untraine
d males 
1) Pl 
2) CR, 
10.5 – 21 
g·d-1  for 4 
wks 
3) β-Al, 
3.2 - 6.4 
g·d-1 for 4 
wks 
4) 
CR+βAl 
(same 
dose as  2 
& 3) 
Not 
measured 
GXT on cycle 
ergometer to 
determine 
VO2peak, VT &LT 
1) no effect 
2) increase* in 
power at VT 
3) increase* in 
power at LT 
4) increase* in 
・O2 and power at 
LT and VT, 
increase in 
%・O2peak at VT 
 
Note. * = significant (p < 0.05), MP = matched-paired, VT = ventilatory threshold, 
β-Al = beta alanine, Pl = placebo, GXT  = graded exercise test, ・O2max  = maximum 
oxygen uptake, HR = heart rate,  HRmax = maximum heart rate, TTE = time to 
exhaustion, TWD = total work done, PWCFT = physical working capacity at the 
fatigue threshold, MLSS = maximal lactate steady state, LT = lactate threshold. 
 
Derave et al. (2007) reported no significant improvement in 400 metre sprint time for 
a group of 15 well-trained 400 metre runners, following four weeks β-alanine 
supplementation (pre: 51.11 ± 1.66 seconds vs. post: 50.36 ± 1.43 seconds, p > 0.05). 
Although not statistically significant, the improvement of 0.35 seconds should be 
viewed in light of the bigger picture. In high-level athletic competition even an 
enhancement of 0.3 to 0.4 of the coefficient of variation would prove to be an 
improvement in top level athletic competition (Hopkins, Hawley & Burke, 1999). It 
could be concluded that 400 metre sprint performance is not limited by intramuscular 
buffering capacity in this population of athletes. In the same group of athletes, peak 
torque was assessed via 5 bouts of 30 maximal knee extensions. During the last two 
bouts peak torque was significantly improved in the β-alanine group following 
supplementation (bout 4: +6.1% and bout 5: +3.8%, p < 0.05), compared to the 
placebo group (bout 4: + 1.0% and bout 5: -0.8%, p > 0.05). These results suggest that 
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β-alanine supplementation can attenuate fatigue during repeated maximal 
contractions, possibly due to an enhanced intracellular buffer capacity. In contrast, 
other authors employing intermittent type exercise protocols have reported less 
convincing findings. Sweeney, Wright, Brice & Doberstein (2010) using 20 
power/strength trained males, employed a double-blind, placebo-controlled study 
using a matched paired design, to assess the effects of five weeks β-alanine 
supplementation (4g·d-1 in first week 6.4g·d-1 four weeks) on fatigue percentage, 
horizontal peak and mean power during repeat sprints. Subjects performed two sets of 
five, five-second sprints, with 45 seconds rest between repetitions, separated by two 
minutes rest between sets. No significant differences (p > 0.05) were reported for 
group, time or the interaction of time x group for peak power, mean power or fatigue 
percentage. A possible reason for the lack of significant findings could stem from the 
protocol employed. It could be questioned whether multiple five-second sprints, with 
a 45 second rest period between, would tax the anaerobic glycolytic system 
sufficiently to elicit metabolic acidosis (Glaister, 2005). It was reported previously 
(Gaitanos, Williams, Boobis & Brooks, 1993) in a similar protocol to that employed 
by Sweeney et al. (2010) that the percentage of energy derived from anaerobic 
glycolysis was considerably reduced during the final sprints. Furthermore, no lactate 
accumulation was apparent during the final sprint and the author proposes that the 
energy for the final sprint was derived from phosphocreatine and aerobic metabolism. 
 Studies assessing the impact of β-alanine supplementation on maximal 
strength have been reviewed in several recent publications (Artioli et al., 2010; 
Culbertson, Kreider, Greenwood & Cooke, 2010; Derave, Everaert, Beeckman & 
Baguet, 2010; Wilson, Wilson, Zourdos, Smith & Stout, 2010). As maximal strength 
has little, if any, effect on endurance performance, the effects of β-alanine 
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supplementation on maximal strength are deemed irrelevant here and will not be 
discussed. The influence of β-alanine supplementation on aerobic parameters yields 
some discrepant findings. In one study (Harris et al., 2006), isometric endurance of 
the knee extensors at 45 to 50 percent maximum voluntary contraction (MVC) was 
improved by 11.4% (p < 0.02) following 14 days β-alanine supplementation (6.4 g·d-
1). Likewise, Ponte, Harris, Hill et al. (2006) reported an 11.1 percent increase in 
isometric endurance of the knee extensors at 45 to 50 percent MVC following a 28 
day supplementation period (6.4 g·d-1). The similar increases in muscle endurance 
reported by Harris et al. (2006) and Ponte et al. (2007) following the two different 
supplementation periods suggests that muscle carnosine can be enhanced and directly 
attenuate fatigue by using a shorter dosing period without the subsequent ergogenic 
effect being attenuated. It is deduced, therefore, that muscular carnosine is augmented 
by similar amounts with a shorter supplementation period, yet to what extent still 
needs to be clarified.  
 Hill et al (2007) reported increases in muscle carnosine concentrations of 58.8 
percent and 80.1 percent with a four and ten week supplementation period, 
respectively. This lead to a 13 percent and 16.2 percent increase (p < 0.05) in total 
work done (TWD) in a cycling capacity test at 110 percent of work rate maximum 
(WRM).  In a recent study (Van Theinen, Van Proeyen, Vanden Eynde, et al., 2009), 
subsequent to eight weeks of β-alanine supplementation (2- 4 g·d-1), mean and peak 
power outputs were improved in a ten minute cycle performance test following a two 
hour endurance cycle. Mean power was enhanced by 5 percent and peak power by 
11.4 percent (p < 0.05) yet there were no differences in lactate and pH levels which 
suggests that the increased buffering capacity enabled subjects to work at a higher 
intensity for the ten minute performance test. Enigmatically, during the two hour 
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endurance bout prior to the sprint performance test, there were no differences in 
lactate or pH between the β-alanine and placebo group, which suggests that sub-
maximal exercise is unaffected by β-alanine supplementation. In a recent study, TWD 
was enhanced following a combined β-alanine supplementation and high-intensity 
training programme (Smith, Walter, Graef et al., 2009). Forty-six males undertook a 
GXT to determine ・O2max, time to exhaustion, ventilatory threshold and TWD. 
Subjects were then randomly assigned to a supplement group ingesting either 6g·d-1 of 
β-alanine or a placebo during six weeks of high-intensity interval training on a cycle 
ergometer. Supplementation continued at a lower absolute dose (3g·d-1) after the first 
21 days. Parameters were measured before, after the first three-weeks, and then upon 
completion of the six week training period. There was a significant (p < 0.05) 
improvement in ・O2max, time to exhaustion and TWD in both groups, following the six 
week training programme. The gains in ・O2max (4.26%, p = 0.010) and time to 
exhaustion (2.80%, p = 0.043) during the three to six week period were only 
significant in the β-alanine group. Other studies assessing the impact of β-alanine 
supplementation on ・O2max, however, have failed to find any improvements following 
supplementation (Hill et al., 2007; Zoeller, Stout, O’Kroy, Torok & Miekle, 2007), 
suggesting that the results reported by Smith et al. (2009) are merely a result of the 
training programme rather than the supplement per se. Nevertheless, β-alanine 
supplementation may be a valuable training aid. Hoffman, Ratamess, Faignbaum et al. 
(2007) examined the effects of 30 days β-alanine supplementation in 26 collegiate 
American football players. For the final nine days of supplementation subjects began 
pre-season training and under went a Wingate test and sprint drills test. Training logs 
were recorded and after training sessions subjects completed questionnaires on 
subjective feelings of soreness, fatigue, and practice intensity. There were no 
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significant differences (p > 0.0.5) between the β-alanine and placebo group for the 
Wingate test, the sprint drills, feelings of soreness or perception of practice intensity. 
Subjects reported significantly lower feelings of fatigue in the β-alanine group 
compared to the placebo group (3.96 ± 0.80 vs. 4.55 ± 0.83 on a 1 to 7 scale, p < 
0.05). There was also a significant increase (p < 0.05) in the training volume during 
bench press exercise in the β-alanine group. This suggests that β-alanine 
supplementation can increase the amount of work done during training, by delaying 
fatigue and reducing subjective feelings of fatigue.   
 Besides enhancing TWD, time to exhaustion and power during aerobic 
exercise, studies assessing the effect of β-alanine supplementation on neuromuscular 
fatigue have also reported promising results, in young (Stout, Cramer, Meilker, et al., 
2006; Stout, Cramer, Zoeller et al., 2007) and ageing populations (Stout, Graves, 
Smith et al., 2008).  A test labelled the physical working capacity at fatigue threshold 
(PWCFT), uses the electromyographic (EMG) amplitude to detect the power output 
that corresponds to neuromuscular fatigue during incremental cycle exercise. Stout et 
al. (2006) recruited 51 untrained males to assess the effects of four weeks β-alanine 
supplementation (6.4g·d-1) on neuromuscular fatigue of the vastus lateralis during 
submaximal cycling at the PWCFT. Beta alanine supplementation resulted in a 14.5 
percent improvement (p < 0.01) in the PWCFT compared with pre-supplementation 
values. There was no change reported in a placebo group. Furthermore, combining β-
alanine supplementation with creatine produced no additive effects (11 percent 
increase in PWCFT, p < 0.05). Stout et al. (2006) concluded that the increase observed 
in PWCFT following β-alanine supplementation was a result of augmented skeletal 
muscle carnosine concentrations thereby enhancing the buffering capacity during 
exercise. Although men possess a greater skeletal muscle carnosine concentration 
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(Mannion et al., 1992) and a superior anaerobic exercise capacity (Mannion, Jakeman 
& Willan, 1995) it appears the ergogenic effects of β-alanine supplementation are not 
restricted to the male sex. In 22 untrained females four weeks β-alanine 
supplementation (3.2 – 6.4g·d-1), enhanced the PWCFT (12.6 percent, p < 0.001), the 
ventilatory threshold (13.9 percent, p < 0.0.01) and the time to exhaustion (2.5 
percent, p < 0.05) during GXT (Stout et al., 2007).  
 The ventilatory threshold is defined as the non-linear rise in ventilation with 
・O2 during a GXT, and is thought to relate to the increased production of carbon 
dioxide caused by the buffering of H+ as it accumulates in the blood during exercise 
(Stout et al., 2006). It has been suggested that the Tlac and the ventilatory threshold 
occur at a similar point when graphically represented (Bearver, Wasserman & Whipp, 
1986). Therefore, many believe there is a close association between the two 
parameters. Beta-alanine supplementation reportedly increased the ventilatory 
threshold in untrained women by 13 percent compared to a placebo group (Stout et 
al., 2007). In contrast, the ventilatory threshold in young men (22.2 ± 3.3 years) was 
not further enhanced by β-alanine supplementation combined with high intensity 
training, when compared to a training only group (Smith, Walter, Kendall, et al., 
2008). More recently, Smith et al. (2009) assessed the combined effect of six weeks 
interval training and β-alanine supplementation (3-6g·d-1) on the ventilatory threshold, 
and several other physiological parameters during a GXT. In agreement with the 
previous research (Smith et al., 2008; Zoeller et al., 2007) there was no improvement 
in the ventilatory threshold other than that imposed by the interval training. Another 
four week study (Zoeller et al., 2007), that assessed the effects of β-alanine (6.4g·d-1) 
and creatine (21g·d-1), alone or in combination, reported that β-alanine alone did not 
have a significant (p > 0.05) effect on ・O2peak, ・O2 at the Tlac or ventilatory threshold. 
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However, ・O2 and power output at the Tlac, and ventilatory threshold, were 
significantly (p < 0.05) improved when β-alanine and creatine supplementation were 
combined. The authors concluded that the increase in power at the Tlac with β-alanine 
supplementation could be due to an augmented H+ buffering capacity in skeletal 
muscle due to increases in carnosine concentrations. In agreement with Zoeller et al. 
(2007) a recent investigation reported no effect of β-alanine supplementation on ・O2 
kinetics. Fourteen physically active male subjects were randomised into two groups. 
One group supplemented with β-alanine (4.8g·d-1) and the other with an identical 
amount of a placebo for four weeks. Subjects performed a six minute cycle ergometer 
test before and after the supplementation period while ・O2 kinetics were recorded and 
blood samples were extracted to assess pH, lactate, bicarbonate and base excess. The 
results indicate that there were no significant (p < 0.05) effect on ・O2 kinetics 
following β-alanine ingestion. On the contrary, the exercise-induced increase in pH 
was reduced by 19 percent compared to the placebo group (p = 0.03). In a different 
study, 17 recreationally active men undertook a GXT prior to four weeks β-alanine 
supplementation (6g·d-1) to assess if heart rate, percentage of heart rate maximum at 
the onset of blood lactate (OBLA),  percentage ・O2max at OBLA and ・O2max were 
altered following supplementation (Jordon, Lukaszuk, Misic & Umoren, 2010). The 
percentage of heart rate maximum at OBLA and percentage ・O2max at OBLA were 
significantly increased (5.6 and 6.5 percent, respectively; p < 0.05) following β-
alanine ingestion. However, the author reported a significant decrease in O2max in 
both relative and absolute terms (-6.3 and -5.7 percent, respectively; p < 0.01) after β-
alanine supplementation. The greater reduction in O2max in relative terms is due to an 
increase in body mass of the β-alanine group. The reduction in O2max weakens some 
of the findings from the investigation. For instance, the enhancement of the 
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percentage O2max at OBLA may not be a true reflection of physiological response to 
the β-alanine supplementation and may merely be a reflection of the decrease in 
O2max and should be interpreted with caution. Secondly, the protocol used to identify 
OBLA was a fixed blood lactate concentration of 4mmol·L-1. Using a fixed blood 
lactate concentration may make identification purposes easier but it does not take into 
account inter-individual variation in blood lactate response nor does it enable the use 
of the Tlac as a flexion point (Faude, Kindermann & Meyer, 2009; Binder, Wonisch, 
Coora, et al., 2008).  
 To summarise, intramuscular carnosine acts as a buffer during high-intensity 
exercise in humans. Individual carnosine concentrations are affected by several 
factors, including gender, training status, the proportion of fast-twitch muscle fibres 
and β-alanine supplementation. Four-to-ten weeks β-alanine supplementation has the 
potential to enhance muscle carnosine concentrations by up to 80 percent. 
Supplementation can increase carnosine levels in both athletic and non-athletic 
populations alike. The ergogenic effects of β-alanine supplementation are evident in 
exercise situations whereby anaerobic energy provision predominates. Single and 
multiple bouts of short-duration, high-intensity exercise are improved following β-
alanine supplementation. Additionally, research suggests that β-alanine 
supplementation can exert an ergogenic effect in exercise scenarios in which the 
intensity is below ・O2max.  
 Therefore, the purpose of this study was to assess, using a double-blind, 
placebo-controlled, repeated measures design, if β-alanine supplementation can 
improve the velocity and the percentage of ・O2max at the Tlac during treadmill running. 
In addition, the・O2, blood lactate, HR and RPE at the Tlac will also be assessed 
following β-alanine supplementation as these parameters have been reported to be 
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affected by supplementation (Baguet et al., 2010; Hoffman et al., 2007; Zoeller et al., 
2007). The Dmax method of measuring the Tlac was preferred to a fixed lactate 
concentration to enable individual response to be identified.  As aforementioned, 
previous research has reported the effectiveness of augmenting muscle carnosine 
concentrations by supplementing with β-alanine for a period of four to ten weeks. The 
ergogenic effects of β-alanine have been reported after supplementing for only two 
weeks. In order to make supplementation with β-alanine more practical the present 
investigation will assess if a five day supplementation period can produce an 
ergogenic effect. 
 
2.7 Hypotheses 
 Primary hypothesis: There will be a significant difference in the running 
velocity at the Tlac between the control, placebo and β-alanine trials following five 
days β-alanine supplementation (50mg·kg-1·d-1). Previous research reported that β-
alanine supplementation increased the power at the Tlac during cycle exercise in 
untrained subjects (Zoeller et al., 2007). It is proposed, therefore, that β-alanine will 
significant improve the velocity at the Tlac during treadmill running.  
 Secondary hypotheses: There will be a significant difference between the 
control, β-alanine and placebo trials, in the percentage of ・O2max at which the Tlac 
occurs, following five days β-alanine supplementation. This will be in conjunction 
with a significant difference in the ・O2 at the Tlac between the three trials. Beta-alanine 
supplementation was recently reported to enhance the percentage of ・O2max at a fixed 
blood lactate concentration in recreationally active subjects (Jordon et al., 2010). 
Furthermore, there will a significant difference in the lactate, HR and RPE response at 
the Tlac between the control, β-alanine and placebo trials. It has been suggested that β-
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alanine supplementation can alter blood lactate response (Baguet et al., 2010), HR 
(Jordon et al., 2010) and RPE (Hoffman et al., 2007). Therefore, these parameters 
were monitored to assess if β-alanine supplementation could alter the response of 
these factors at the Tlac.  
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3. Method 
3.1 Participants 
 A group of 6 (4 males, 2 females) healthy, recreationally active individuals 
participated in the study. Participants’ anthropometric data is displayed in table 3.1. 
Participants inclusion criteria were: 1) aged < 45 years, 2) being free from illness, 
disease or injury for a month prior to the start in of the study, 3) having a resting heart 
rate and blood pressure < 90 bpm and 160/100mmHg, respectively, 4) not currently 
taking any nutritional supplements, 5) being a non-smoker, 6) being habitually active 
and accustomed to physical exertion. Exclusion criteria included: 1) aged > 45 years, 
2) having a current illness or injury within the last month, 3) having a resting heart 
rate and blood pressure > 90 bpm and 160/100mmHg, respectively, 4) currently 
taking any nutritional supplements, 5) having been a regular smoker in the past, 6) 
being habitually inactive and unaccustomed to physical exertion. All were informed 
of the purpose of the study and associated risks prior to signing consent forms 
(Appendix A) and taking part. A risk assessment was compiled before the onset of 
testing and health questionnaires (appendix B) were completed prior to each testing 
session. The protocol was approved by the University of Chester Ethics Committee. 
 
 
Table 3.1 Subjects descriptive characteristics (n=6). 
 Age  
(years) 
Weight 
(kg) 
Height 
(cm) 
BMI 
(kg/m2) 
・O2max  
(ml·kg-1·min-1) 
・O2max  
(L·min-1) 
Mean 27.83 68.43 172.52 22.80 53.26 3.66 
SD 2.48 10.85 9.59 1.36 7.81 0.83 
Note. M = mean; SD = standard deviation; BMI = body mass index; ・O2max = 
maximum oxygen uptake 
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3.2 Experimental Design 
 This double-blind, placebo-controlled, repeated measures experimental design 
(figure 3.2) was chosen over the more popular matched paired design due to the 
stronger statistical within-subjects comparison (Atkinson & Nevill, 2001; Winter, 
Eston & Lamb, 2001). Participants were asked to refrain from any exhaustive exercise 
and from consuming alcohol and caffeine in the 48 hours prior to each testing session. 
This was assessed via verbal confirmation from the individual prior to testing. 
Participants were instructed to keep to their usual dietary and exercise regimes and 
replicate them in the 48 hours prior to each trial. Additionally, participants were 
instructed to refrain from exercising on the day of testing. This was assessed via 
verbal confirmation from the participant. It has been suggested that diet has little 
influence on muscle carnosine levels (Baguet et al., 2009). Therefore, participants 
were not asked to record their food intake. Following the first visit to the lab for 
・O2max assessment, trial order (control, placebo and β-alanine) was randomly assigned 
for the participants remaining three visits. Following the placebo and β-alanine trials a 
three week washout period was incorporated to allow for any supplement-induced 
carnosine increase to be hydrolysed and eliminated. With a typical supplementation 
period of 28 days, carnosine increases are reported to be augmented by about 42 
percent (Harris et al., 2006). It is proposed the five-day supplementation period 
employed in the current study has the potential to increase carnosine concentrations 
by 7 to 10 percent. With the elimination of carnosine occurring at about four percent 
per week (Baguet et al., 2009), a three week washout period would be sufficient to 
return carnosine concentrations to pre – supplementation levels. Testing took place 
between the hours of 10am and 6pm. With the exception of one individual, 
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participants were tested at the same time of day for all trials in order to eliminate any 
effects due to circadian rhythms (Atkinson & Reilly, 1996).     
 
 
 
 
 
 
 
 
 
Figure 3.2. Diagrammatic representation of the double-blind, placebo-controlled, 
repeated measures cross-over experimental design (n = 6). 
 
 
3.2.1 ・O2max 
 On the first of four visits to the Human Performance Laboratory participants 
undertook a maximal treadmill (HP Cosmos, Pulsar, Nussdorf, Germany) test to 
assess ・O2max and familiarise participants to laboratory procedures. Anthropometric 
data was collected barefoot and in light weight clothing.  Respiratory gases were 
assessed breath by breath via open-circuit spirometry (Cosmos, Quark, b2, Cosmed 
S.r.l, Rome, Italy). The Quark b2 was calibrated prior to each session using a 3 litre 
syringe for flow volumes across a wide range of flow rates and known gases for CO2 
and O2 concentrations. Heart rate (HR) was continuoulsy monitored using  FSI Polar 
Heart Rate monitors (Polar Electro Oy, Kempele, Finland). RPE was taken during the 
Control 
Placebo Β-alanine
Control 
Placebo 
Β-alanine
 
o2max / 
Familiaris
ation  
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last 30 seconds of each 3 minute stage (appendix C) using Borg’s 6 – 20 scale (Borg, 
1998). The test was preceded by a 5 minute warm-up during which the intensity was 
selected by the participant and replicated for subsequent trials. The face mask (Hans 
Rudolf, Kansas City, USA) used to collect respiratory gases was fitted following the 
warm-up. After which, the treadmill gradient was increased to one percent to replicate 
the energy costs of outdoor running (Jones & Doust, 1996) and a starting speed of 7 
km·h-1 was selected. The speed was increased by 1 km·h-1 every 3 minutes until 
volitional exhaustion. The data for the last minute of each 3 minute stage was 
averaged over the final 30 seconds. The highest 30 second average for ・O2 was 
recorded as the ・O2max. Criteria for the attainment of ・O2max were two or more of the 
following: 1) no increase in HR with an increase in exercise intensity, 2) a respiratory 
exchanged ratio of >1.1, 3) a lactate concentration of > 8mM, 4) an RPE of > 17 on 
the on the Borg scale and 5) a plateau in ・O2 (Whaley et al, 2006). 
 
 3.2.2 Lactate threshold 
 On remaining visits to the Human Performance Laboratory participants were 
assessed for Tlac and the ・O2 at Tlac using a discontinuous 3 minute stage treadmill 
protocol. On arrival to the laboratory a finger tip blood sample was taken and 
analysed immediately for lactate using a portable lactate analyser (Lactate Pro, Arkray 
Inc, Kyoto, Japan). A puncture site (index or middle finger) was selected and cleaned 
with an alcohol pad. The area was allowed to dry and then wiped with a cotton pad to 
remove any residue alcohol, to prevent the blood from becoming haemolysed (Maw, 
Locke, Cowley & Witt, 2000). The sampling finger was held firmly and punctured 
into the pulp and across the finger using a single-use lancet. The first drops of blood 
were wiped away with a cotton pad as it may have been contaminated with other 
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bodily fluids. Moderate pressure was applied to the finger to ensure adequate blood 
flow and the sample was collect in Lactate Pro strips (Arkray Inc, Kyoto, Japan) and 
analysed by the Lactate Pro analyser. The protocol was the same as that described for 
the assessment of ・O2max, except that after completion of each stage, a fingertip blood 
sample was taken (as described above) as the participant straddled the moving 
treadmill belt. The blood sampling procedure took between 20 and 40 seconds and 
then the participant resumed running at the next intensity. The Tlac was calculated via 
the Dmax method (Cheung et al., 1992). Individual graphs were plotted, with treadmill 
speed (km·h-1) on the x axis and lactate concentration (mmol·L-1) on the y axis (figure 
3.3). A straight line was then fitted between the two end lactate points and the 
maximal perpendicular distance from the fitted line was taken as the Tlac. ・O2 at the 
Tlac was calculated from the same graph by the addition of a secondary y axis. The ・O2 
that corresponded to the Tlac was taken as the ・O2 at the Tlac. For example, in figure 
4.2 the velocity and ・O2 at the Tlac corresponds to 12km·h-1 and 37.71ml·kg-1·min-1, 
respectively. This was done for all participants across all three trials. Appendix D 
shows an example from one for the participants. HR at Tlac was taken as the average 
HR over the last 30 seconds of the velocity corresponding to the Tlac.  
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Figure 3.3. Lactate threshold graph depicting the velocity and ・O2 at the at the lactate 
threshold calculated via the Dmax method (Cheung et al., 1992). 
   
 
 
3.2.3 Supplementation. 
 During the course of the study participants were asked to refrain from taking 
any other nutritional supplements. Participants were instructed to take 50 mg·kg-1·d-1 
of β-alanine, or an equal amount of placebo (maltodextrin), for five consecutive days. 
This was based on the observations and recommendation of Hoffman et al. (2007) 
whose work suggests that participants should be given doses relative to body weight. 
Following the familiarisation/・O2max session, the 50 mg·kg-1·d-1 of β-alanine and 
placebo were weighed out, according to each participant’s weight, and put into 
gelatine capsules. The capsules were then separated into five envelopes for each 
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participant, with each envelope containing one days worth of β-alanine or the placebo. 
Participants were instructed to take no more than two capsules (≤ 800g) in any one 
dose and disperse the supplements equally throughout the day, with at least three 
hours between separate doses. This was in order to attempt to keep the participants 
blind to the substance they were ingesting as doses in excess of 800g of β-alanine 
have been reported to cause paresthesia (Harris et al., 2006). The supplements were 
identical in taste and appearance. A certificate of analysis for the β-alanine can be 
found in appendix E and confirms that it was 100 percent pure β-alanine. 
   
 3.2.4 Statistical analysis 
The data met criteria for normal distribution. Data are, therefore, presented as means 
plus or minus the standard deviation (±SD). A repeated-measures analysis of variance 
(ANOVA) was performed to detect within-subject differences between the three trials 
(control, placebo and β-alanine), for the velocity, the・O2, the percentage of ・O2max,  
the lactate concentrations, the HR and the RPE at Tlac. All data met the assumptions 
for sphericity (p > 0.05). An α level of p < 0.05 was chosen to indicate statistical 
significance. Data was analysed using SPSS for Windows (version 17.0, 2008, 
Chicago, IL). 
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4. Results 
 Participants ingested β-alanine or a placebo for five days prior to undertaking 
a Tlac test. A control trial was also performed where participants undertook a Tlac test 
without ingesting any ergogenic substances. The velocity, percentage ・O2max, ・O2, 
lactate, HR and RPE at the Tlac were measured for all trials.  Table 4.1 displays the 
mean (±SD) for the velocity, percentage ・O2max, ・O2, HR and RPE at the Tlac for all 
three trials. One of the participants contracted the influenza virus prior to one of the 
testing sessions and therefore the control results were calculated with the data from 5 
participants. 
    
Table 4.1. Mean (± S.D.) for Velocity, percentage of ・O2max, ・O2, heart rate and RPE 
at the lactate threshold for all three trials 
 
 
Trial 
Control (n = 5) Β-alanine (n = 6) Placebo (n = 6) 
Velocity at Tlac 
(km·h-1) 10.83 ± 1.16 10.17 ± 0.98 10.33 ± 1.03 
%・O2max at Tlac 
(%) 69.94 ± 7.39 75.21 ± 6.84 75.93 ± 7.32 
・O2 at Tlac  
(ml·kg-1·min-1) 37.16 ± 5.68 40.21 ± 7.63 40.38 ± 6.29 
Lactate at Tlac 
(mmol·L-1) 4.0 ± 1.8 4.1 ± 1.2 3.7 ± 1.5 
HR at Tlac 
(BPM) 168.8 ± 13.9 165.6 ± 16.3 166.4 ± 11.6 
RPE at Tlac 14.4 ± 1.7 14.0 ± 2.5 
 
13.6 ± 2.3 
 
Table 4.1 gives an overview of the measured parameters. The velocity at the Tlac was 
reduced during the β-alanine and placebo trials. The o2 at Tlac was increased 
following β-alanine supplementation and this was also true during the placebo trial. 
Therefore, percentage of o2max at Tlac also increased during the β-alanine and 
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placebo trials. Lactate values compared to the control trial were increased in the β-
alanine trial and attenuated in the placebo trial. HR and RPE response was reduced in 
the treatment trials compared to the control. The results for each parameter measured 
are presented in greater depth below. 
   
4.1 Body mass 
 Participants mean body mass during the testing period remained relatively 
stable. Mean body mass at the beginning of testing was not significantly different to 
that recorded at the end of the testing period (68.43 ± 10.85 vs. 68.81 ± 11.45 kg, p = 
0.497). Changes in ・O2 kinetics, therefore, reflect response to treatments rather than 
fluctuations in body mass. 
 
 
  4.2 Velocity at the lactate threshold 
 Mean ± SD for the velocity at the Tlac was 10.83 ± 1.16, 10.17 ± 0.98 and 
10.33 ± 1.03km·h-1 for the control, β-alanine and the placebo trial, respectively (figure 
4.2). The velocity at the Tlac was reduced by 4.6% in the placebo trial, and reduced by 
an additional 1.8% in the β-alanine trial, when compared to the control trial. A 
repeated measures ANOVA revealed that there was no significant differences 
between the three trials (p = 0.369).  
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Figure 4.2 Mean ± (SD) velocity at the lactate threshold for all trials. 
 
  
4.3 Lactate threshold as percentage of ・O2max  
 Mean ± SD for the percentage ・O2max at the Tlac was 69.94 ± 7.39, 75.21 ± 
6.84 and 75.93 ± 7.32% for the control, β-alanine and the placebo trial, respectively. 
The increase in the percentage of ・O2max at the Tlac is displayed in figure 4.2. There 
was a 5.27% increase in the percentage ・O2max in the β-alanine trial and a 5.99% 
increase in the placebo trial, compared to control trial. A repeated-measures ANOVA 
revealed that there were no significant differences between the control, β-alanine or 
the placebo trials (p = 0.087).  
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Figure 4.3 Mean ± (SD) of the percentage of ・O2max at the lactate threshold. 
 
 
4.4 ・O2 at the Tlac  
 Mean ± SD for the ・O2 at the Tlac was 37.16 ± 5.68, 40.21 ± 7.63 and 40.38 ± 
6.29ml·kg-1·min-1 for the control, β-alanine and the placebo trial, respectively. There 
was a 8.2% increase in the ・O2 at the Tlac in the β-alanine trial and a 8.7% increase in 
the ・O2 at the Tlac in the placebo trial, compared to the control trial/ The repeated-
measures ANOVA revealed that there were no significant variations in ・O2 values at 
the Tlac between the three trials (p = 0.103). Figure 4.4 shows a boxplot illustrating the 
spread of data for the ・O2 at the Tlac for all three trials. Participant number 5 is shown 
as an outliner on the graph due to the unusually low ・O2 value during the control trial, 
when compared to the mean. 
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Figure 4.4. Mean ± (SD) of ・O2 response at the Tlac across the three trials. 
 
4.5 Lactate at the Tlac 
 Mean ± SD for the lactate concentrations at the Tlac was 4.0 ± 1.8, 4.1 ± 1.2 
and 3.7 ± 1.5 mmol·L-1 for the control, β-alanine and the placebo trial, respectively. 
Figure 4.5 shows the individual lactate concentrations at the Tlac for the three trials. 
There was a 10% reduction in lactate levels at the Tlac during the placebo trial and a 
2.5% increase in lactate concentrations at the Tlac in the β-alanine trial, when 
compared to the control trial. The repeated measures ANOVA uncovered no 
significant variations in lactate response at the Tlac between the three trials (p = 
0.628).    
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Figure 4.5 Individual participants mean lactate concentrations across the three trials. 
 
4.6 HR at the Tlac 
 Mean ± SD for the HR at the Tlac was 168.8 ± 13.9, 165.6 ± 16.3 and 166.4 ± 
11.6 beats·min-1 for the control, β-alanine and the placebo trials, respectively. There 
was a 1.9% reduction in the HR at the Tlac in the β-alanine trial and a 1.4% reduction 
in HR at the Tlac in the placebo trial, when compared to the control trial.  The repeated 
measures ANOVA revealed no significant variation in HR at the Tlac between the 
three trials (p = 0.626). In 5 out of 6 subjects HR was lower during the β-alanine trial 
than the placebo or control trials (figure 4.6).  
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Figure 4.6 Individual heart rate responses at the Tlac during the three trials. 
 
 
4.7 RPE at the Tlac 
 Mean ± SD for the RPE score (6 to 20 scale) at the Tlac was 14.4 ± 1.7, 14.0 ± 
2.5 and 13.6 ± 2.3 for the control, β-alanine and the placebo trials, respectively. In 3 
out of the six participants β-alanine reduced the RPE score at the Tlac (figure 4.7). 
When compared to the control trial, there was a 2.8% reduction in RPE response at 
the Tlac in the β-alanine trial and a 5.6% reduction in RPE response at the Tlac in the 
placebo trial. The repeated measure ANOVA revealed the variation in RPE scores 
between the three trials was not significant (p = 0.289). 
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Figure 4.7 Individual RPE response across all trials 
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5.0. Discussion  
 The current study is the first to examine the effects of a β-alanine 
supplementation on various physiological parameters at the Tlac, using a five day 
supplementation protocol. The primary finding is that short term β-alanine 
supplementation does not have a significant effect on the velocity or the 
percentage・O2max at the Tlac. The primary hypothesis can, therefore, be rejected as five 
days β-alanine supplementation had no significant effect on the velocity at the Tlac. 
Secondary findings suggest that there is no effect of β-alanine supplementation on 
percentage of ・O2max, ・O2, blood lactate concentrations, HR or RPE at the Tlac.  This is 
inconsistent with previous research which reported a significant increase in the power 
at the Tlac (Zoeller et al., 2007) and percentage ・O2max and HR at OBLA (Jordon et al., 
2010), following β-alanine supplementation. The discrepancies between the findings 
of the current study and that of Zoeller et al. (2007) could be related to several factors. 
Firstly, β-alanine was co-ingested with creatine in the study by Zoeller et al. (2007); 
whereas in the present study it was ingested alone. Interestingly, in the group that 
ingested β-alanine on its own there was no effect on ・O2 at the Tlac. Secondly, the dose 
of β-alanine differs between the two studies. The present study experimented with a 
dose of approximately 3.4g·d-1 for five days; in comparison to the 3.2 g·d-1 for 28 days 
used by Zoeller et al (2007). Intramuscular carnosine was not measured in this study 
or in the study by Zoeller et al (2007). Therefore it cannot be said with any confidence 
whether muscle carnosine concentrations were amplified or not. Based on previous 
research that measured muscle carnosine before and after supplementation (Baguet et 
al., 2009; Derave et al., 2007; Harris et al., 2006; Harris et al., 2009; Hill et al., 2007), 
carnosine content increased by 37 to 80 percent when supplementing for a period of 4 
to 10 weeks. Therefore, it is highly likely that muscle carnosine levels were increased 
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in the study by Zoeller et al. (2007). The same cannot be assumed in the present study 
as this was the first to examine the use of a five day dosing protocol.  Nevertheless, in 
a recent study using a 28 day dosing protocol (Baguet et al., 2010) there was no 
reported influence of β-alanine supplementation on ・O2 throughout a GXT. Finally, 
the mode of exercise differs between this study and Zoeller et al. (2007). Beta-alanine 
supplementation has been reported to be ergogenic in cycling (Hill et al., 2007; Stout 
et al., 2006; Stout et al., 2007; Stout et al 2008; Smith et al., 2009; Van Thienen et al., 
2009; Zoeller et al., 2007), running (Jordon et al., 2010) and rowing (Baguet et al., 
2010). With the majority of research being conducted using a cycle ergometer it 
remains to be elucidated as to whether β-alanine supplementation can delay fatigue in 
alternative exercise modes.  
 In research using a running protocol (Jordon et al., 2010), HR and percentage 
・O2max at which OBLA occurred where significantly different following β-alanine 
supplementation. However, the increase in the percentage・O2max at which OBLA 
occurred is a reflection of the concomitant decrease in ・O2max and increase in body 
mass. The results of the study should, therefore, be interpreted with caution. . In the 
present investigation five days β-alanine supplementation had no significant effect on 
the percentage ・O2max or HR at the Tlac. Four out of the five subjects showed a 
reduction in HR at the Tlac following β-alanine supplementation (figure 4.6). However 
with closer examination, three out of these four subjects also showed reductions in the 
velocity at the Tlac and, therefore, the reduction in HR is a consequence of a reduced 
exercise intensity rather than a treatment effect. In the study by Jordon et al. (2010), 
HR was significantly greater at OBLA in the β-alanine group, whereas there was no 
difference in the placebo group. The experimental design employed in the present 
study (repeated measures) favours a stronger statistical comparison compared to a 
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matched-pairs design due to between-individual variation (Atkinson & Nevill, 1999). 
Furthermore, the protocol used by Jordon et al. (2010) to assess OBLA is 
inappropriate for assessing the changes in running performance. The majority of 
running events are not predominantly ran on a continuous inclination, so the choice to 
assess OBLA using an incline GXT raises questions as to how effective would β-
alanine supplementation would be during level running (Midgley et al., 2007). The 
author cannot recall any sporting event whereby the gradient is increased every three 
minutes until the athlete becomes exhausted. In the present investigation, which 
employed a 1 percent treadmill gradient to represent the energy cost of outdoor 
running (Jones & Doust, 1996), β-alanine supplementation did not have an effect on 
HR or percentage ・O2max at which the Tlac occurred. 
 The main theory explaining the ergogenic effect of β-alanine supplementation 
proposes that the surplus of β-alanine serves as a precursor for enhanced carnosine 
synthesis in skeletal muscle thereby augmenting the intramuscular buffering capacity 
(Harris et al., 2006). In the present investigation the mean lactate concentrations 
between the three experimental trials were not significantly different (p < 0.05). This 
is in agreement with previous research (Baguet et al., 2010). In the latter 
investigation, muscle acidosis was attenuated without a concomitant alteration in 
lactate concentrations. The author concluded that the reduced acidosis represented a 
better buffering capacity and not a reduction in anaerobic energy delivery. In the 
current study, despite the non significant differences in lactate concentrations, there 
was a 2.5 percent increase in lactate levels at the Tlac in the β-alanine trial, in 
conjunction with a reduced velocity at the Tlac. This suggests that the ingested β-
alanine did not augment the intramuscular buffering capacity in this population of 
subjects, possibly a consequence of the shorter dosing period employed in the study. 
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In two out of the six subjects there was a reduction in lactate concentrations at the 
Tlac, but in only one of these subjects was the velocity at the Tlac kept constant across 
the baseline and β-alanine trials. Therefore, the reduced lactate of one of these 
subjects is likely due to reductions in exercise intensity. On the other hand, variations 
in carnosine synthetase activity (Tsubone et al., 2007) and/or β-alanine transport 
(Bakardjiev & Bauer, 1994) between subjects, due to differing training statuses 
(Parkhouse et al., 1985; Tallon et al., 2005) may mean carnosine synthesis occurs at 
different rates. It could be postulated that some subjects may possess an enhanced 
buffering capacity in a shorter amount of time because of these factors. In these select 
few a shorter dosing period may be adequate to augment muscle carnosine 
concentrations. Further research is warranted to be able to advise athletes with 
confidence. 
 Beta-alanine supplementation had no significant effect on the RPE response at 
the Tlac in the present study. This is similar to the findings of Jordon et al. (2010) who 
reported no change in RPE at the termination of a GXT following β-alanine 
supplementation. In contrast, Hoffman et al. (2007) reported a significant (p ≤ 0.05) 
decrease in subjective feelings (7-point rating scale, 1 = fresh and 7 = tired) of fatigue 
in 26 college American football players following 30 days β-alanine supplementation 
when compared to a placebo group (3.96 ± 0.80 vs. 4.55 ± 0.83). The validity and 
reliability of the 7-point rating scale could be questioned and partly explain the 
significant finding on perceived fatigue. The present study and that of Jordon et al. 
(2010) used a traditional RPE scale of 6 to 20, which is valid and reliable (Borg, 
1998). It should be noted that the aerobic nature of the exercise performed in the 
current study is in contrast to the anaerobic type of exercise assessed in the study by 
Hoffman et al. (2007). On the assumption that an all-out effort was required for the 
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Wingate test, the line drills and during the resistance training programme, any 
increase in carnosine concentrations would serve to reduce feeling of fatigue in this 
type of exercise, for the same absolute exercise intensity. However, the reduced 
perception of practice intensity in the β-alanine group (3.92 ± 0.60, 1 to 7 scale) 
compared to the placebo group (4.18 ± 0.40), although not significant (p > 0.05), may 
represent a reduced effort during training and consequently reduced feelings of 
fatigue.  
 The inconstancies highlighted between this research and that from other 
laboratories (Baguet et al., 2010; Hoffman et al., 2007; Jordon et al., 2010; Zoeller et 
al., 2007) are partly related to variation in exercise type, participant training status, 
experimental design and supplement dose. It is, therefore, important to highlight some 
limitations in the present study that may have affected the outcome. Firstly, muscle 
carnosine concentrations were not measured at any point during the investigation. 
Several recently published studies (Baguet et al., 2010; Jordon et al., 2010; Sweeney 
et al., 2010) also neglected to measure carnosine concentration during the course of 
their studies. However,  previous clinical trials (Bageut et al., 2009; Derave et al., 
2007; Harris et al., 2006; Harris et al., 2009; Hill et al., 2007) assessing β-alanine 
supplementation have measured intramuscular carnosine content before and after the 
supplementation period, using the biopsy technique or using proton magnetic 
resonance spectroscopy. In all these studies intramuscular carnosine concentrations 
were enhanced by 27 to 80 percent. The large variation in the response can be 
attributed to the type of the muscle sampled, the dose and length of supplementation 
and the training status of the participants. Nevertheless, all subjects reported 
improvements in carnosine concentrations to some degree. The majority of studies 
(Bageut et al., 2009; Baguet et al., 2010; Derave et al., 2007; Harris et al., 2006; 
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Harris et al., 2009; Hill et al., 2007; Hoffman et al., 2007; Jordon et al., 2010; Stout et 
al., 2006; Stout et al., 2007; Stout et al., 2008; Sweeney et al., 2010; Van Theinen  et 
al., 2009; Zoeller et al., 2007) utilised, at least, a 28 day supplementation period. 
Some studies have demonstrated an ergogenic effective of β-alanine supplementation 
employing a 14 day protocol (Harris et al., 2006; Ponte et al., 2007). Although 
intramuscular carnosine concentrations were not measured in these investigations, 
significant reductions in fatigue were noted. In the present study, the effects of a five 
day supplementation period were assessed. Having not measured intramuscular 
carnosine concentrations it cannot be said with any certainty whether this 
supplementation period is sufficient to increase carnosine concentrations. Based on 
the exploratory work of Harris et al. (2006) 28 days of β-alanine supplementation 
(3.2g·d-1) was suffice to elicit a 42 percent increase in muscle carnosine 
concentrations. This equates to a 1.5 percentage increase in muscle carnosine 
concentrations per day. The average dose in the present study was 3.4g·d-1 so in 
theory participants could potentially have enhanced carnosine concentrations by at 
least 7.5 percent. However, without measuring intramuscular carnosine concentrations 
this cannot be confirmed. It could be hypothesised that an increase of such magnitude 
was insufficient to enhance the buffering capacity of the active musculature, which 
typically stands between 7 and 15 percent of the total muscle buffering capacity 
(Harris et al., 2006; Mannion et al., 1995; Tallon et al., 2005).  
 Another limitation in the present study relates to the three week washout 
period encompassed within the experimental design. This is a repercussion of not 
knowing, with any conviction, how much a shorter β-alanine supplementation period 
augments muscle carnosine content. It is, therefore, difficult to estimate how much 
carnosine was hydrolysed during the three week washout period. Intramuscular 
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carnosine is a relatively stable compound due to the lack of the carnosine dipeptiase 
activity in muscle cells (Otani et al., 2005). Bageut et al. (2009) divided participants 
into high (n =3) and low responders (n = 5) with regards to carnosine increases and 
washout response. The high responders demonstrated a 55 percent increase in muscle 
carnosine content and showed a washout response of 3.5 percent per week. The low 
responders showed a 15 percent increase in carnosine content and a washout rate of 
2.5 percent per week. In terms of time, this corresponded to a washout period of 15 
and 7 weeks for the high and low responders, respectively. If the proposed increase in 
carnosine content (≥7.5 percent) held true in the present study, and all participants 
were low responders, it would take approximately three weeks to hydrolyse the 
supplementation-induced carnosine increases. Thereby, muscle carnosine content 
would be at pre-supplementation levels for the next testing session.  Therefore, in 
theory a three week washout period should be sufficient to eliminate any 
supplementation-induced changes in muscle carnosine content, although further work 
is warranted in regards to carnosine dynamics and individual response. There has 
been no work to date that has assessed the impact of training on muscle carnosine 
hydrolysis. The participants in the study by Baguet et al. (2010) were reported to be 
“physically active but not involved in regular training.” Two of the participants in the 
present study were soccer players who began pre-season training during the course of 
the study. Consequently carnosine synthesis rate (Parkhouse et al., 1985; Tallon et al., 
2005) and physiological response during the subsequent Tlac test (Smith et al., 2009; 
Smith et al., 2009) may have been a result of training induced adaptations rather than 
a response to β-alanine supplementation. Furthermore, training may have affected 
carnosine washout rate. If training increases carnosine synthesis (Tallon et al., 2005) 
it could be possible that the washout rate is concomitantly reduced. If this were the 
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case then this may have had implications during subsequent testing session after the 
three week washout period. 
 There are limited side effects reported in the literature following β-alanine 
ingestion. A harmless, yet commonly occurring, side effect is paresthesia (Artioli et 
al., 2010; Derave et al., 2010). When single doses in excess of 800mg are consumed, 
symptoms of paresthesia are reported 20 to 25 minutes after ingestion and subside 
within approximately one hour. This was first reported by the intuitive work of Harris 
et al. (2006); surprisingly however, few labortatories have reported treatment blinding 
issues during investigations. In the present study, three out of the six participants 
reported symptoms of paresthesia following ingestion of β-alanine, despite not 
ingesting more than two capsules (< 800mg) in a single dose. Therefore, the double-
blinding of treatments was unsuccessful during this investigation and may have 
impacted on the results. Recently, a controlled release formulation of β-alanine was 
trialled to attempt to reduce the reported symptoms of paresthesia (Harris et al., 2009). 
Muscle carnosine was augmented by 40 percent after four weeks of supplementation 
and participants ingested 1600mg in a single dose without any symptoms of 
paresthesia. This may improve compliance during investigations and make 
supplementing more practical as fewer doses will be required. For example, one 
participant in the current study had to take > 10 capsules each day, interspersed with 
at least two hours between doses. If this had been a ten week supplementation period, 
as employed in some investigations (Hill et al., 2007), compliance may not have been 
as good. Participants in the current study verbally confirmed that their compliance 
with supplementation was 100 percent.  
   Participants in the current study were asked to maintain their usual dietary 
practices and replicate them in the 48 hours prior to each testing session. This was 
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assessed via verbal confirmation from the participant before each session. It can 
therefore, be assumed that dietary intake of carnosine and β-alanine was kept 
relatively stable during the testing period. One of the participants was a pescetarian 
and given the influence of meat ingestion on carnosine content (Harris et al., 2007) 
this participant may have had lower carnosine concentrations to begin with and so 
may therefore be expected to respond to a greater extent following β-alanine 
supplementation. Some fish (tuna and mackerel) are reported to have greater dipeptide 
content than poultry and meat (Abe, 2000) suggesting that carnosine concentrations in 
pescetarians may not be all that different from omnivores (Harris et al., 2007). 
Furthermore, the lack of a significant positive correlation between carnosine content 
and meat ingestion reported by Baguet et al. (2009) emphasises that diet does not 
greatly affect muscle carnosine content.  
 Another apparent limitation in the current investigation is the sample size. A 
previous power calculation estimated that for an effect size of 0.20 (i.e. detection of 
the smallest worthwhile effects, 20%) and an alpha level of 0.05 (detection of non 
existent effects, 5%), 27 participants would be required to enable significant 
differences to be identified. Based on the variation about the means and the SD across 
the trials for velocity at the Tlac, it is calculated that 57 participants would be required 
to detect the smallest worthwhile change in the velocity at the Tlac. In addition, this 
investigation utilised a 1 km·h-1 increase in treadmill velocity every three minuets. 
This protocol may not be sensitive enough to detect changes in the velocity at Tlac 
(Faude et al., 2009). Therefore, with a greater sample size and a protocol with smaller 
increments in treadmill velocity at each stage, short term β-alanine supplementation 
may prove to be ergogenic at the Tlac during treadmill running. 
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5.1. Recommendation for future research 
 Research on β-alanine supplementation is still in it infancy. The results of the 
present study indicate that a shorter dosing period is ineffective at improving the Tlac 
in recreationally active individuals. Future research should attempt to elucidate the 
optimum dosing strategy to maximise muscle carnosine concentrations and as to what 
extent this augments muscle buffering capacity and exercise performance. At present 
the diversity across studies in the supplement amount and the length of the dosing 
period makes prescribing the optimum dosing protocol difficult. Shorter 
supplementation periods (< 14 days) should be explored to examine the effect on 
muscle carnosine conconcentrations. This would make supplementing more practical 
for athletes and exercise enthusiasts. Research with athletes holds promise (Derave et 
al., 2007; Van Thienen et al., 2009). More work is warranted on β-alanine 
supplementation and carnosine dynamics in high-level athletes to depict if carnosine 
levels are increased to the same degree as in less conditioned individuals. The effect 
of long term training could influence the rate of carnosine synthesis subsequent to 
exercise performance (Smith et al., 2009). In addition, the effect of training on 
carnosine washout following β-alanine supplementation is an area still unexplored. 
Further work to assess the dynamics of carnosine after β-alanine supplementation-
induced increases would enable more quality repeated-measures, placebo controlled, 
cross-over design research studies to be conducted; thereby allowing stronger 
statistical comparisons to be made. Future research needs to examine the effects of β-
alanine supplementation and muscle carnosine content across different sports and 
assess its effect on performance. Extending our knowledge about the physiological 
diversity of carnosine (Begum et al., 2005) would help to determine which exercise 
situations β-alanine supplementation would provide the greatest ergogenic effect. 
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With only one side effect being reported with β-alanine supplementation it appears 
that the short term side effects are sparse and are not of any harm to health. On the 
other hand the long term (>10 weeks) health consequences of β-alanine 
supplementation are presently unknown. Given that β-alanine is a naturally occurring 
amino acid found abundantly in the tissue of animals, it is likely to be safe (Artioli et 
al., 2010). Nevertheless, future studies using a ten week plus supplementation period 
need to share any adverse effects reported by participants. 
  
 
 
5.2 Conclusion 
 It can be concluded from the current data that five days β-alanine 
supplementation has no ergogenic effect on the velocity or the percentage of ・O2max at 
the Tlac during treadmill running. Participants undertook three Tlac test on separate 
occasions. One was a control trial and the other two were following a five day 
supplementation period with 50mg.kg-1 of β-alanine or a placebo. There was no 
significant difference in the velocity at the Tlac between the control, the placebo or the 
β-alanine trial. Likewise, there was no significant difference in percentage of ・O2max 
following β-alanine supplementation when compared to the placebo or control trial. 
Therefore, the primary hypothesis can be rejected. This suggests that either five day 
β-alanine supplementation does not allow sufficient time to synthesise and augment 
intramuscular carnosine concentrations, or that the exercise-induced increases in 
acidosis at the Tlac can be buffered with normal physiological concentrations of 
carnosine, and further carnosine increases fail to enhance the Tlac. Furthermore, there 
were no significant differences in the ・O2, lactate concentrations, heart rate or RPE at 
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the Tlac. Collectively, these results suggest that β-alanine is not an effective 
performance enhancing nutritional supplement for long distance running. Further 
research in which a typical 28 day supplementation period is employed is warranted 
to support or refute the results of the present investigation. 
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7. Appendices 
Appendix A 
 
CONSENT FORM 
 
Effect of Beta Alanine Supplementation on the Lactate Threshold during 
Treadmill Running 
 
 
Please tick the box if you agree with the statement: 
 
 
1. I confirm that I have read and understood the participant information sheet for the 
above-named study, and have had the opportunity to ask the lead researcher any 
questions. 
 
 
2. I understand that my participation is voluntary, and that I am free to withdraw from 
participating in the study at any time, without giving any reason and without my 
rights being affected. 
 
 
3. I agree that the data collected from the study can be used in the writing of a 
scientific report and should the report be deemed creditable the data used in the report 
can be published.  
 
 
4. I agree to take part in the above study. 
 
 
Name of participant  ………………………………………………………… 
 
Date    ………………………………………………………… 
 
Signed    ………………………………………………………… 
 
 
Name of researcher  ………………………………………………………… 
 
Date    ………………………………………………………… 
 
Signed    …………………………………………………………. 
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Appendix B 
Pre-test Health Questionnaire 
 
Personal Information 
 
Name:_________________________________  Test date:   
 
Address:________________________________________________________ 
 
Contact number:____________________________ Date of birth:___________ 
 
 
In order to ensure that the physiological assessments are as safe and accurate as possible, it is 
important that each participant is screened for any factors that may influence the results.  
Please circle your answer to the following questions: 
 
1. Has your doctor ever said that you have a heart condition and that you should 
only perform physical activity recommended by a doctor? 
 
2. Do you feel pain in the chest when you perform physical activity? 
 
3. In the past month, have you had chest pain when you were not performing 
physical activity? 
 
4. Do you lose your balance because of dizziness or do you ever lose 
consciousness? 
 
5. Do you have bone or joint problems (e.g. back, knee or hip) that could be made 
worse by a change in your physical activity? 
 
6. Is your doctor currently prescribing any medication for you? 
 
If yes please provide details: __________________________ 
     __________________________ 
     __________________________ 
     __________________________ 
 
7. Are you pregnant, or have you been pregnant in the last six months? 
 
8. Have you injured your hip, knee or ankle joint in the last six months? 
 
9. Do you know of any other reason why you should not participate in physical 
activity? 
 
YES/NO 
YES/NO 
YES/NO 
YES/NO 
YES/NO 
YES/NO 
YES/NO 
YES/NO 
YES/NO 
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Appendix C 
RPE instructions 
 
Borg (1998) provides specific instructions for the use of his 6 – 20 RPE scale which 
should be reiterated to participants during each exercise session. He states: 
 
“While exercising we want you to rate your perception of exertion, i.e., 
how heavy and strenuous the exercise feels to you. The perception of 
exertion depends mainly on the strain and fatigue in your muscles and 
on your feeling of breathlessness or aches in the chest.  
 Look at this rating scale; we want you to use this scale from 6 to 20, 
where 6 means “no exertion at all” and 20 means “maximal exertion.” 
 
9 corresponds to “very light” exercise. For a normal healthy 
person it is like walking slowly at his or her own pace for some 
minute. 
 
13 on the scale is “somewhat hard” exercise, but it still feels OK 
to continue. 
 
17 “very hard” is very strenuous. A healthy person can still go 
on, but he or she really has to push him- or herself. It feels vary 
heavy, and the person is tired. 
 
19 on the scale is an extremely strenuous exercise level. For 
most people this is the most strenuous exercise they have ever 
experienced. 
 
Try to appraise your feelings of exertion as honestly as possible, 
without thinking about what the actual physical load is. Don’t 
underestimate it, but don’t overestimate it either. It’s your own feeling 
of effort and exertion that’s important, not how it compares to other 
people’s. What other people think is not important either. Look at the 
scale and the expressions and then give a number.  
 Any questions?”  
 
This will be used to inform participants of how to use the RPE scale for 
every exercise testing session. 
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Appendix D  
Lactate threshold graph 
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Appendix E 
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Appendix F  
 
・O2max/Tlac Treadmill Protocol Data Collection Sheet 
 
Participant:  __________________  D.O.B:  ___________ 
 
Date:  ___________ 
 
Session:     Signed consent form:  YES/NO  
 
Height (cm):    Weight (Kg): 
 
BMI:      BP:  
 
NB each stage lasts 3 minutes 
 
 
Stage 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
6 
 
 
7 
 
 
Speed 
(Km/h) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gradient 
(%) 
 
1.0 
 
1.0 
 
1.0 
 
1.0 
 
1.0 
 
1.0 
 
1.0 
 
HR (bpm) 
       
・O2 
 (ml·kg-
1·min-1) 
       
 
RPE 
       
 
Lactate 
(mM) 
       
 
RER 
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Appendix G – screenshot of a participants raw o2 data 
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Appendix H – SPSS data 
 
Velocity at the lactate threshold 
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Percentage of o2max at the lactate threshold 
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o2 at the lactate threshold 
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Lactate at the lactate threshold 
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Heart rate at the lactate threshold 
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RPE at the lactate threshold 
 
 
 
 
 
 
 
 
